CAMBRIDGE, England, October 5, 2012
CAMBRIDGE, England, October 5, 2012 /PRNewswire/ --
Crescendo Biologics Limited (Crescendo) today announces it has received Notice of Allowance of US 12/476,087 (a continuation of its granted patent US 7,541,513) which covers mice in which the endogenous immunoglobulin lambda light chain locus is functionally deleted.
This further extends coverage of the core Crescendo patent family which includes the European patent EP1399559 (inventors: BrĂźggemann et al.) which was originally granted on 30thApril 2008 to the Babraham Institute and was subsequently assigned to Crescendo. All the key claims of EP1399559 were upheld by the Opposition Division on 4thApril 2011.
Crescendo has already made use of its ability to knock out lambda light chain to generate proprietary 'triple knockout' mice that have the immunoglobulin heavy chain, kappa light chain and lambda light chain loci all functionally deleted. This is a significant advance over previous knockout mice which retain intact lambda light chain. Â
Knockout of lambda light chain expression, in addition to knockout of heavy chain and kappa light chain, is important for the efficient generation of human heavy chain antibodies in a transgenic mouse. Therefore the triple knock out background is core to Crescendo's mouse platform which provides fully-human, in vivo-matured VH fragments, and will be used in the development of differentiated products for the company's in-house pipeline and for partnering.
About Crescendo Biologics Ltd
Crescendo Biologics is building a pipeline of novel medicines based on its highly innovative VH antibody fragment platform through both in-house development and strategic partnerships. Crescendo's proprietary VH technology produces human heavy chain-only antibodies in transgenic mice providing a unique source of fully human VH fragments that have matured in vivo to have high affinity, stability and solubility. VH fragments are the smallest antibody fragments that retain binding affinity and specificity offering the potential to generate novel products with improved drug-like properties and able to address unmet medical needs.
Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The company has raised funding totalling ÂŁ7.7 million from an investment consortium led by Sofinnova Partners with Avlar BioVentures, Babraham Bioscience Technologies, and the Rainbow Seed Fund.
ContactsMike Romanos/Amanda Bettison Crescendo Biologics Tel: +44(0)1223-497140 Email: email@example.comChris Gardner Citigate Dewe Rogerson Tel: +44(0)207-638-9571 Email: firstname.lastname@example.orgPR Newswire
Last updated on: 05/10/2012